ArticleCureus2026
Challenges in Predicting Intubation in Patients With Severe Coronavirus Disease 2019 (COVID-19) on High-Flow Nasal Cannula: A Focus on Lymphopenia and Conventional Markers.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Intubation risk assessment in severe coronavirus disease 2019 (COVID-19) remains a key clinical challenge, especially for patients treated with high-flow nasal cannula (HFNC). We aimed to clarify whether lymphopenia at admission is associated with the subsequent need for intubation. Methods This retrospective study included all consecutive COVID-19 patients admitted to Saitama Red Cross Hospital in Saitama, Japan, from July to September 2021, who required HFNC therapy at presentation. Intubation was performed if the saturation of peripheral oxygen (SpO₂) remained below 90% despite HFNC with a fraction of inspired oxygen (FiO₂) of 80%. We compared clinical and laboratory characteristics between patients who required intubation and those successfully managed on HFNC to identify prognostic factors present at the time of HFNC initiation. Results Out of 49 analyzed patients, 15 required intubation during hospitalization and 34 did not. Age and body mass index (BMI) were similar between groups. The Mann-Whitney U tests showed significantly lower lymphocyte counts (intubation: 739.1/μL (interquartile range (IQR) 516.3) vs. non-intubation: 909.0/μL (IQR 423.4); p=0.034), lower lymphocyte percentage (8.0% (IQR 13.0) vs. 15.6% (IQR 9.6); p=0.037), and longer hospital stays (17 days (IQR 18) vs. 14 days (IQR 10); p=0.007) in the intubation group. Multivariate stepwise logistic regression identified lower lymphocyte count (OR 0.997; 95% CI: 0.995-1.000; p=0.048) and longer hospital stay (OR 1.09; 95% CI: 1.01-1.20; p=0.036) as independent indicators of intubation. Conclusion In severe COVID-19 patients treated with HFNC, admission lymphopenia was independently associated with subsequent intubation; however, its discriminative performance as a prognostic marker was modest. Lymphocyte counts may aid prognostic risk stratification when interpreted cautiously alongside conventional clinical markers and oxygenation indices, particularly in the context of current and future respiratory viral outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.